Difference between revisions of "Salsalate"

From Self-sufficiency
Jump to: navigation, search
m (Removed Category:Benzoates; Adding category Category:Salicylates (using HotCat))
 
m (1 revision)
 
(No difference)

Latest revision as of 21:17, 21 September 2010

Salsalate
File:Salsalate.svg
Systematic (IUPAC) name
2-(2-Hydroxybenzoyl)oxybenzoic acid
Identifiers
CAS Number 552-94-3
ATC code N02BA06 (WHO)
PubChem CID 5161
DrugBank DB01399
Chemical data
Formula C14H10O5
Molar mass 258.23 g/mol[[Script error: No such module "String".]]
  (verify)
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Salsalate is a non-steroidal anti-inflammatory drug (NSAID). Salsalate is in a class of drugs called salicylates. Salsalate may work by inhibiting the production of and release of prostaglandins. Salsalate is the generic name of a prescription drug marketed under the brandnames Mono-Gesic, Salflex, Disalcid, and Salsitab. Other generic and brand name formulations may be available.[1]

Typical Use

Salsalate is used to reduce pain and inflammation caused by conditions such as rheumatoid arthritis, osteoarthritis, and related rheumatic conditions. Salsalate is also recommended by physicians as an anti-inflamatory alternative to naproxen, and ibuprofen for patients that have had minor stomach bleeding or stomach upset. It has also been used as an alternative to narcotic pain medicine for people with spinal disc protrusion.



"In contrast to aspirin, salsalate causes no greater fecal gastrointestinal blood loss than placebo." [2]

Research on use to prevent or treat Type II Diabetes

The Wall Street Journal Health Blog reported on research on using Salsalate to prevent or treat type II diabetes: "In a 20-patient, month-long study, the fasting glucose levels of those who took salsalate declined 13% compared with those who took a placebo. The results, published in the Feb. issue of Diabetes Care, suggest that the drug reduces blood sugar in obese adults who don’t have diabetes, apparently by making insulin work better."[3]

On March 20th, 2010, The Joslin Diabetes Center , Boston, MA, released a report entitled: Generic Drug for Type 2 Diabetes Passes Next Clinical Hurdle - "Salsalate, an anti-inflammatory agent, shows encouraging results in preliminary trial"[4]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
Pyrazolidine/Butylpyrazolidines
Acetic acid derivatives
and related substances
Oxicams
Propionic acid derivatives
Fenamates
Coxibs
Other

M: MUS, DF+DRCT

anat (h/n, u, t/d, a/p, l)/phys/hist

noco(m, s, c)/cong(d)/tumr, sysi/epon, injr

proc, drug (M1A/3)

Non-steroidal anti-inflammatory drug (NSAID) products (primarily M01A and M02A, also N02BA)
Salicylates
Arylalkanoic acids
2-Arylpropionic acids
(profens)
N-Arylanthranilic acids
(fenamic acids)
Pyrazolidine derivatives
Oxicams
COX-2 inhibitors
Sulfonanilides
Topically used products
COX-inhibiting nitric oxide donators
Others
Items listed in bold indicate initially developed compounds of specific groups. †Withdrawn drugs. ‡Veterinary use medications.
es:Salsalato vi:Salsalate
  1. ↑ drugs.com Salsalate entry [1]
  2. ↑ DrugBank: DB01399 (Salsalate)
  3. ↑ Aspirin cousin could help prevent diabetes blogs.wsj.com
  4. ↑ Generic Drug for Type 2 Diabetes Passes Next Clinical Hurdle
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Salsalate&oldid=40576"